ArticleNeurology and therapy2023

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States.

Daniel Kantor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.